GPT and metabolic dysfunction-associated steatohepatitis: Furthermore, they showed the ability to discriminate MASH from simple steatosis with serum GP73 levels alone in the subgroup of patients with MASLD with persistently normal ALT, reporting that 58 (55.2%) patients were accurately identified with MASH using serum GP73 alone